## Aurobindo Pharma Limited (AUROPHARMA) Stock Analysis - December 20, 2024

This report analyzes Aurobindo Pharma Limited's stock performance and financial health based on the provided data to determine whether it's a buy, sell, or hold.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | AUROPHARMA                |
| Company Name     | Aurobindo Pharma Limited   |
| Industry         | Pharmaceuticals           |
| Listing Date     | July 19, 2000             |
| ISIN             | INE406A01037              |


**1.2 Market Data:**

| Metric                | Value      |
|-----------------------|------------|
| Last Price            | 1,241.00   |
| Change                | -13.70     |
| % Change              | -1.09%     |
| Previous Close        | 1,254.70   |
| Open                  | 1,254.80   |
| Close                 | 1,241.70   |
| VWAP                  | 1,261.43   |
| Week High             | 1,592.00   |
| Week Low              | 958.50    |
| Sector PE             | 19.88      |
| Symbol PE             | 20.25      |
| Total Traded Volume  | 1,843,118  |
| Delivery Quantity     | 1,055,381  |
| Delivery %            | 57.26%    |
| CM Daily Volatility   | 1.71       |
| CM Annual Volatility  | 32.67      |


**1.3 Pre-Open Market Data:**

The pre-open market data shows a slight downward trend, with the final pre-open price (1254.8) being slightly higher than the last price (1241).  However, the volume is low (1376).

**1.4 Corporate Actions:**

| Ex-Date      | Purpose                     |
|--------------|-----------------------------|
| August 26, 2024 | Annual General Meeting      |
| July 30, 2024  | Buy Back                    |
| February 20, 2024 | Interim Dividend - Rs 1.50  |
| November 20, 2023 | Interim Dividend - Rs 3.00  |
| ...           | ...                         |  *(Further historical dividend data available)*


**1.5 Recent Announcements (Last 7):**

| Broadcast Date    | Subject                                      |
|--------------------|----------------------------------------------|
| December 21, 2024 | Press Release                                 |
| December 17, 2024 | Loss/Duplicate-Share Certificate-XBRL         |
| December 17, 2024 | Loss of Share Certificates                    |
| December 17, 2024 | General Updates                              |
| December 13, 2024 | Action(s) initiated or orders passed          |
| December 13, 2024 | Press Release                                 |
| December 13, 2024 | Change in Directors/ Key Personnel/ Auditor   |


**1.6 Financial Results (Last Five Quarters):**

| Quarter Ending     | Income (₹)     | Expenditure (₹) | Profit After Tax (₹) | EPS (₹) |
|---------------------|----------------|-------------------|-----------------------|---------|
| September 30, 2024 | 294,725        | 222,350           | 53,753                | 9.21    |
| June 30, 2024      | 252,541        | 207,917           | 32,904                | 5.62    |
| March 31, 2024     | 301,700        | 223,712           | 57,867                | 9.88    |
| December 31, 2023 | 302,316        | 233,594           | 62,378                | 10.65   |
| September 30, 2023 | 273,584        | 222,606           | 41,574                | 6.48    |


**1.7 Shareholding Patterns:**

Promoter holding has remained relatively stable around 51.8% over the last year, showing minimal fluctuation.


**1.8 Key Directors and Contact Information:**

*(List of Directors and contact information for Aurobindo Pharma Limited is available in the provided data.)*


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (1,241.00) is below the previous close (1,254.70), indicating a downward trend.
* It's significantly below the week high (1,592.00) and above the week low (958.50).
* Pre-open activity showed a slightly higher price than the closing price, suggesting some buying interest.

**2.2 Financial Performance:**

* Income and profit after tax show some fluctuation but generally positive trends over the last five quarters.
* EPS also shows some variation but generally positive trends.  Note that there is a significant drop in EPS from Q3 2024 to Q4 2024.

**2.3 Shareholding Analysis:**

* Promoter holding is consistently high (around 51.8%), indicating strong management confidence.  Slight decreases in promoter holdings are observed in recent quarters.

**2.4 Corporate Action Summary:**

* Recent dividends suggest a commitment to returning value to shareholders.
* The buyback indicates management's belief in the company's undervalued stock.

**2.5 Volatility and Risk:**

* Daily and annual volatility metrics (1.71 and 32.67 respectively) suggest moderate to high risk.  Further analysis of historical volatility would be beneficial.

**3. Final Verdict:**

Based solely on the provided data, the recommendation is **Hold**.

**Reasoning:**

While the company shows generally positive financial performance with consistent promoter holdings and a history of dividend payouts, the recent price drop, moderate to high volatility, and the significant drop in EPS from Q3 2024 to Q4 2024 raise concerns.  The buyback is a positive sign, but the impact of this action on the stock price is yet to be fully determined.  More data and analysis are needed to confidently recommend a buy.  The current situation warrants a "hold" until further information clarifies the recent downward trend and the impact of the buyback.

**Conclusion:**

Aurobindo Pharma shows signs of both strength (consistent promoter holdings, dividend history, buyback) and weakness (recent price drop, volatility, EPS drop).  A "hold" strategy is recommended pending further analysis and clarification of recent trends.  Additional data points, such as industry benchmarks and future growth projections, would significantly improve the accuracy of this analysis.
